Azymetric -Tailored Multifunctional Therapeutics
by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases. Two is better than one. Create novel mechanisms of action through unique binding. Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting.
Enhance efficacy, simply and efficiently
Azymetric™ antibodies possess the desirable drug-like features of naturally occurring antibodies, including:
- Long serum half-life and high stability
- Ability to mediate effector function
- Low immunogenicity risk
Azymetric™ antibodies are compatible with standard manufacturing processes with high yields and purity.
- Use conventional antibody purification and manufacturing processes
- Rapidly screen target and sequence combinations for bispecific activities in the final therapeutic
The core of the Azymetric™ therapeutic platform consists of proprietary amino acid modifications in the heavy and light chains of an antibody that enable the transformation of monospecific (single target) antibodies into bispecific antibodies, which can simultaneously bind to two distinct locations on a target or two targets.
Azymetric™ antibodies are compatible with glyco-engineering and other Fc modifications, including the EFECT™ Platform, to enhance therapeutic activity.
Unlike many other bispecific platforms, Azymetric™ enables the generation of fully IgG-like antibodies and is compatible with alternative target binding formats (e.g. Fabs, scFvs, and VHHs) and antibody-drug conjugates.